Study: HCQ in hospitalised COVID-19 patients is associated with reduced mortality

Discussion in 'Covid-19 News/Info' started by DonGlock26, Sep 8, 2020.

  1. DonGlock26

    DonGlock26

    Messages:
    74,386
    Likes Received:
    71,801
    Joined:
    Jan 18, 2001
    Another large study finds HCQ effective in saving lives.
    The
    Henry Ford Hospital study was also large.

    "Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

    Published:August 25, 2020DOI:https://doi.org/10.1016/j.ejim.2020.08.019

    Abstract

    Background
    Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19.

    Objective
    We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality.

    Methods
    In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores, with the addition of subgroup analyses.

    Results
    Out of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients receiving or not HCQ were 8.9 and 15.7, respectively. After adjustment for propensity scores, we found 30% lower risk of death in patients receiving HCQ (HR=0.70; 95%CI: 0.59 to 0.84; E-value=1.67). Secondary analyses yielded similar results. The inverse association of HCQ with inpatient mortality was particularly evident in patients having elevated C-reactive protein at entry.

    Conclusions
    HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within the limits of an observational study and awaiting results from randomized controlled trials, these data do not discourage the use of HCQ in inpatients with COVID-19.


    https://www.ejinme.com/article/S0953-6205(20)30335-6/fulltext "
     
  2. diamondd2

    diamondd2

    Messages:
    1,883
    Likes Received:
    1,799
    Joined:
    Apr 23, 2010
    In before Facebook and Twitter take it down.
     
    catman71 and DonGlock26 like this.

  3. DonGlock26

    DonGlock26

    Messages:
    74,386
    Likes Received:
    71,801
    Joined:
    Jan 18, 2001
  4. flyover

    flyover

    Messages:
    18,026
    Likes Received:
    49,431
    Joined:
    Oct 25, 2012
    Location:
    Western Kansas
    Big Pharma does not like HCQ, Fauci does not like HCQ. Big Pharma can't make a gazillion on HCQ and it is said that Fauci has a 15% stake in on of the vaccine companies.
     
    catman71 and DonGlock26 like this.